Go to Advanced Search
PTEN |
LOCUS ID | 5728 | ||||||||||||||||
GENE_SYMBOL | PTEN | ||||||||||||||||
GENE NAME | phosphatase and tens | ||||||||||||||||
SYNONYMNS | BZS, DEC, CWS1, GLM2, MHAM, TEP1, MMAC1, PTEN1, 10 | ||||||||||||||||
CHROMOSOME | 10 | ||||||||||||||||
HOMOLOGENE ID | 265 |
microRNAs | miR-21/152 | 22956257 |
GENE SUMMARY |
---|
This gene was identified as a tumor suppressor that is mutated in a large number of cancers at high frequency. The protein encoded this gene is a phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase. It contains a tensin like domain as well as a catalytic domain similar to that of the dual specificity protein tyrosine phosphatases. Unlike most of the protein tyrosine phosphatases, this protein preferentially dephosphorylates phosphoinositide substrates. It negatively regulates intracellular le |
OBSERVATIONS |
---|
Complication | Evidence | PMID |
Nephropathy | 1. The suggest the following molecular etiopathophysiology of DN(i) hyperglycemia upregulates IGF2, which initiates PTEN, a regulator of IGF2 sigling; (ii) loss of this IGF2-PTEN feedback loop causes changes that are characteristic of DN; and (iii) lowered expression of the repair modulator SPARC in the development and/or progression of DN. Hence, targeting relevant modulators, such as like IGF2, PTEN, and SPARC, may be important in the magement of DN. | 20929508 |
Neuropathy | 1. Collectively, these findings identify a novel therapeutic approach, potentially applicable to other neurological conditions requiring specific forms of molecular knockdown, and also identify a unique target, PTEN, to treat diabetic neuroregenerative failure. | 24578546 |
Insulin resistance and inflammation | 1. Moreover, the two datasets combined generated a single molecular network that further identified PTEN (a phosphatase) as a unique new link between insulin signaling, IR, and apoptosis reflecting the pathophysiology of "metabolic syndrome". | 19960405 |